RxDoctor Payments Data

Christopher Stansbury

Optometrist · Charleston, WVNPI 1376569814

Payments from drug & device makers

What this record shows

9 manufacturers reported payments, led by Rxsight Inc at 47.5% of the total. Reporting peaked in 2024 at $1,313 and has fallen 78.0% since, to $289 in 2025.

$2,154in general payments, 2019–2025

Across 49 payments — averaging $43.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$1K
  • AbbVie$597
  • Alcon$326
  • Bausch & Lomb Americas Inc.$110
  • Johnson & Johnson Surgical Vision, Inc.$26
  • Harrow Eye, LLC$24
  • plus $48 from 3 others

What the payments were for

  • Consulting fees$1,00046%
  • Food & beverage$1,15454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,154 in reported general payments places this provider in the 70th percentile of 210 optometrist providers in West Virginia.

See all optometrist providers in West Virginia

Medicare billing

Part B allowed, 2024
$97,128
Medicare patients
479
Services billed
1,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine106$99,154
LumiganBimatoprost171$77,840
Cyclosporine25$11,403
VyzultaLatanoprostene Bunod26$9,617
CombiganBrimonidine Tartrate/Timolol26$9,114
Azelastine Hcl175$4,081
Fluorometholone38$3,184
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$2,965
Loteprednol Etabonate21$2,899
Dorzolamide-TimololDorzolamide/Timolol/Pf16$2,317
Latanoprost232$2,200
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat117$2,051
Brimonidine Tartrate13$1,470
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha105$1,302
MoxifloxacinMoxifloxacin Hcl42$1,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$597$186,107303 claims
Bausch & Lomb Americas Inc.Vyzulta$110$9,61726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 210 optometrist providers in West Virginia.

Other optometrist in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →